Panel Discussion | Hot Topics in Antegrade Approach

Saturday, March 7, 2026

11:47 AM - 12:05 PM EST

Location: International Ballroom Center

Moderator(s)

Carlo Di Mario, MD

Professor
University of Florence
Florence, Toscana, Italy

Disclosure(s): Amgen: Grant/Research Support (Terminated, July 1, 2024); BSC: Grant/Research Support (Ongoing); Novo Nordisk: Grant/Research Support (Ongoing)
Stephane Rinfret, MD, SM

Director of Complex Coronary Interventions
Georgia Heart Institute
Gainesville, Georgia, United States

Disclosure information not submitted.

Panel Discussant(s)

Lindsey Cilia, MD

Co-Director of Complex Coronary Therapeutics Program Interventional Cardiologist
Inova Heart and Vascular Institute/Virginia Heart
Falls Church, Virginia, United States

Disclosure(s): No financial relationships to disclose
Jeffrey W. Moses, MD, FSCAI

John and Myrna Daniels Professor of Cardiology
Columbia University Medical Center
New York, New York, United States

Disclosure(s): Abiomed (spouse): Consulting Fees (e.g., advisory boards) (Ongoing); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stock Options [in privately held companies] (Ongoing); Covanos: Stock Options [in privately held companies] (Ongoing); seimens: Consulting Fees (e.g., advisory boards) (Ongoing); Weightless Lead: Stock-privately held company (Ongoing)
Debabrata Dash, MD, DM, FICC, FSCAI, FAPHA, , FACC, FESC

Consultant Interventional Cardiologist
Aster Hospital, Al Mankhool Dubai, UAE
Dubai, Dubai, United Arab Emirates

Disclosure(s): No financial relationships to disclose
Angela M. Taylor, MD, MS, MBA

Professor
University of Virginia
Charlottesville, Virginia, United States

Disclosure information not submitted.
MP

Megha Prasad, MD

Assistant professor
Columbia University

Disclosure information not submitted.
Seung-Woon Rha, MD, PhD, FACC

Professor
Korea University Guro Hospital
Seoul, Republic of Korea

Disclosure(s): No financial relationships to disclose
Masahisa Yamane, MD

Senior Advisor
Saitama Sekishinkai Hospital
Tokyo, Tokyo, Japan

Disclosure(s): Asahi Intecc, Japan: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

Disclosure(s):

Carlo Di Mario, MD: Amgen: Grant/Research Support (Terminated, July 1, 2024); BSC: Grant/Research Support (Ongoing); Novo Nordisk: Grant/Research Support (Ongoing)

Lindsey Cilia, MD: No financial relationships to disclose

Jeffrey W. Moses, MD, FSCAI: Abiomed (spouse): Consulting Fees (e.g., advisory boards) (Ongoing); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stock Options [in privately held companies] (Ongoing); Covanos: Stock Options [in privately held companies] (Ongoing); seimens: Consulting Fees (e.g., advisory boards) (Ongoing); Weightless Lead: Stock-privately held company (Ongoing)

Debabrata Dash, MD, DM, FICC, FSCAI, FAPHA, , FACC, FESC: No financial relationships to disclose

Seung-Woon Rha, MD, PhD, FACC: No financial relationships to disclose

Masahisa Yamane, MD: Asahi Intecc, Japan: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)